No products in the cart.
Rabbit Polyclonal Phospho-ERalpha (S106) antibody (STJ90263)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, IF, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:40000;
Recommended protocols: check protocols
Click or hover above images to see image description for ERalpha (phospho Ser106) Polyclonal Antibody.
Check alternative names for the antibodyExpand
ESR1 antibody, ESR antibody, NR3A1 antibody,|DKFZp686N23123 antibody|ER alpha antibody|ER antibody|ER-alpha antibody|Era antibody|ESR antibody|ESR1 antibody|ESR1_HUMAN antibody|ESRA antibody|Estradiol receptor antibody|Estrogen nuclear receptor alpha antibody|Estrogen receptor 1 antibody|Estrogen receptor alpha 3*,4,5,6,7*/822 isoform antibody|Estrogen receptor alpha antibody|Estrogen receptor alpha delta 3*,4,5,6,7*,8*/941 isoform antibody|Estrogen receptor alpha delta 3*,4,5,6,7*/819 2 isoform antibody|Estrogen receptor alpha delta 4 +49 isoform antibody|Estrogen receptor alpha delta 4*,5,6,7*/654 isoform antibody|Estrogen receptor alpha delta 4*,5,6,7,8*/901 isoform antibody|Estrogen receptor alpha E1 E2 1 2 antibody|Estrogen receptor alpha E1 N2 E2 1 2 antibody|Estrogen receptor antibody|ESTRR antibody|NR3A1 antibody|Nuclear receptor subfamily 3 group A member 1 antibody|Anti-Estrogen Receptor alpha antibody [E115] – ChIP Grade (ab32063)
SCBT cat No: sc-242022|sc-242026|sc-242025|sc-245215|sc-245234|sc-163801|sc-101902|sc-162584|sc-162586|sc-245256|sc-240033|sc-247666|sc-139226|sc-245304|sc-514440|sc-242049|sc-138158|sc-163818|sc-163819|sc-514159|sc-242055|sc-245364|sc-245362|sc-245365|sc-514699|sc-514707|sc-242068|sc-136736|sc-160185|sc-390887|sc-390559|sc-393065|sc-167299|sc-240057|sc-240056|sc-398999|sc-398998|sc-81862|sc-245464|sc-245465|sc-245468|sc-241243|sc-245470|sc-137978|sc-137980|sc-515388|sc-393861|sc-242108|sc-242107|sc-245492|sc-393896|
ERalpha (phospho Ser106) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-ERalpha (S106) Polyclonal Antibody detects endogenous levels of ERalpha protein only when phosphorylated at S106.
Synthesized phospho-peptide derived from ERalpha (phospho Ser106) at AA range 40-120
WB, IHC, IF, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:40000;
|Molecular weight|| |
ERalpha (phospho Ser106) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
ERalpha (phospho Ser106) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Estrogen receptor antibody, ER antibody, ER-alpha antibody, Estradiol receptor antibody, Nuclear receptor subfamily 3 group A member 1 antibody
|Protein names|| |
Estrogen receptor , ER , ER-alpha , Estradiol receptor , Nuclear receptor subfamily 3 group A member 1
|Protein function|| |
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
|Protein tissue specificity|| |
Widely expressed. Isoform 3 is not expressed in the pituitary gland.
|Involvement in disease|| |
Estrogen resistance (ESTRR) [MIM:615363]: A disorder characterized by partial or complete resistance to estrogens, in the presence of elevated estrogen serum levels. Clinical features include absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, reduced bone mineral density, osteoporosis, continued growth into adulthood and very tall adult stature. Glucose intolerance, hyperinsulinemia and lipid abnormalities may also be present. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. The modulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains a ligand-dependent transactivation domain, also known as E/F or AF-2 domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and act in a promoter- and cell-specific manner. AF-1 seems to provide the major transactivation function in differentiated cells. / Belongs to the nuclear hormone receptor family. NR3 subfamily. / Contains 1 nuclear receptor DNA-binding domain.
|Protein post-translational modifications|| |
Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation. Dephosphorylation at Ser-118 by PPP5C inhibits its transactivation activity. Phosphorylated by LMTK3 in vitro. / Glycosylated; contains N-acetylglucosamine, probably O-linked. / Ubiquitinated. Deubiquitinated by OTUB1. / Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization. / Palmitoylated (isoform 3). Not biotinylated (isoform 3). / Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.
|Protein cellular localization|| |
Nucleus / Cytoplasm / Cell membrane / Peripheral membrane protein / Cytoplasmic side / Nucleus / Cytoplasm / Cell membrane; Peripheral membrane protein; Cytoplasmic side / Cell membrane; Single-pass type I membrane protein / Nucleus / Golgi apparatus / Cell membrane
AntibodyPlus can customize ERalpha (phospho Ser106) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: